

Student Name:				

2024-2025 HEALTH FACULTY IMMUNIZATION CLEARANCE FORM

Student Name:	
Student ID Number:	
Date of Birth:	
Country of Birth:	
Program:	



https://www.albertahealthservices.ca/assets/info/hp/cdc/if-hp-cdc-ipsm-imm-recomm-hcs-high-risk-occ-prg-appdx-a-08-302.pdf)

VACCINE	AHS GUIDELINE	RESULTS:
TETANUS, DIPHTHERIA, PERTUSSIS	 All students must have a primary series of 3 or more documented doses of tetanus/diphtheria containing vaccine, including a reinforcing dose within the last 10 years. All students must have documentation of a dose of acellular pertussis containing vaccine (Ex. Tdap) on/after the age of 18 - Regardless of when the most recent dose of tetanus was. If the student has no documentation – complete a primary series of 3 doses of tetanus, diphtheria, pertussis at the appropriate intervals. 	Document the last three tetanus, diphtheria, pertussis containing immunizations: Dose #1: Dose #2: Dose #3: Most recent dose: for most students this will be the adult Tdap at >18 yrs. If the most recent dose was administered when the student was <18 years of age, the form will be considered incomplete. *The most recent dose must be within the last 10 years*

Last edited: 22 March 2024

^{*} COPIES OF ALL ORIGINAL & NEW IMMUNIZATION RECORDS AND TEST RESULTS MUST BE SUBMITTED WITH THIS FORM.

^{**} A minimum of a month and year is REQUIRED for a vaccine dose to be considered valid.

^{***} Submitting pending & completed copies of this form (& attachments) to the faculty is the <u>responsibility of the student</u>. The UHC cannot legally release this information to the faculty on your behalf as a result of the Health Information Act (HIA)

^{**** &}quot;It is the responsibility of the Health Care Student and students in other High-Risk Programs to initiate and follow through with the assessment of their immunization status with their occupational health or student health services program (Alberta Health Services. (2022). *Immunization Recommended for Health Care Students and Students in Other High-Risk Occupational Programs.*

Student Name:		

POLIO	 All students must have a primary series of 3 or more documented doses of polio-containing vaccine with at least 1 dose administered after the age of 4 years. 	Document the <u>last three</u> polio containing vaccine doses: Dose #1:				
		Dose #2:				
	AND					
	All students must also have documentation of a single lifetime reinforcing dose of polio-containing vaccine	Dose #3 (>4 years of age):				
	on/after the age of 18. This dose should be administered at least 10 years after the completion of the primary series.	□ Date of one time ADULT BOOSTER (>18 years of age) dose if 10				
	If the student has no documentation – complete a primary	or more years since last dose:				
	series of 3 doses of polio-containing vaccine at the appropriate intervals.	<u>OR</u>				
		□ Booster not applicable as <10 years since last dose.				
TUBERCULOSIS	1-step TST result in millimeters (mm) within 12 months of the program start date.	Date of TST:				
TESTING (TST)	BCG vaccination is NOT a contraindication to a TST.	Date of Reading: Result: mm				
	A Chest X-Ray without written documentation of a positive TST in millimeters will NOT be accepted.	Chest X-Ray: (Required if current TST is positive or there is a history of a positive TST)				
	If there is documentation of a previously positive TST in	Date:				
	millimeters – only a Chest X-Ray is required within 6 months of the program start date.	Result: NORMAL ABNORMAL NOT APPLICABLE				
	*REPORT MUST BE ATTACHED.	Referral to TB Services ? □ YES □ NO				
VARICELLA	2 doses of varicella-containing vaccine after 12 months of age at appropriate intervals. Students who have 1 dose of varicella-	Dose #1:				
(Chicken Pox)	containing vaccine should be offered a second dose. OR	Dose #2:				
	POSITIVE Varicella IgG serology results.	OR				
	 If Varicella IgG results are negative or indeterminate - Vaccination is required. Adults need 2 doses with a minimum interval of 6 weeks between doses. 	Varicella Serology COPY OF LAB RESULT MUST BE ATTACHED TO THIS FORM Date:				
	*Serology after vaccination is <u>not recommended</u> .	Result: POSITIVE NEGATIVE / INDETERMINATE NOT APPLICABLE				

Last edited: 22 March 2024

Student Name:					

MEASLES, MUMPS & RUBELLA	 2 valid doses of measles-containing vaccine after 12 months of age. 2 valid doses of mumps-containing vaccine after 12 months of age. 1 valid dose of rubella-containing vaccine after 12 months of age is legislated under the Alberta Public Health Act. 	MMR: Dose #1: Dose #2: OR Measles: Dose #1: Dose #2: Mumps: Dose #1: Dose #2: Dose #1: Dose #2:
HEPATITIS B VACCINATION	Serological testing in the absence of immunization records will NOT be accepted. All students must have documentation of a complete Hepatitis B immunization series. An acceptable primary series can be 2-4 doses depending on the age and geographic area in which it was administered. Positive serology (Anti-HBs) will NOT be accepted if there is an incomplete or absent record of immunization, unless the student has serology that indicates previous infection.	Dose #1: Dose #4: Dose #2: Dose #5: Dose #3: Dose #6: Dose #7:
HEPATITIS B BLOOD TESTING	The Hepatitis B serology recommendations for health care students differ based on the students' risk of past Hepatitis B infection. Not at risk of past infection: A Hepatitis B Surface Antibody (Anti-HBs) is required At risk of past infection: A Hepatitis B Surface Antibody (Anti-HBs), Hepatitis B Core Antibody (Anti-HBs), Whepatitis B Core Antibody (Anti-HBc), Hepatitis B Antigen (HBsAg) are required. (High Risk: Students who have immigrated to Canada from a Hepatitis B endemic country (see Appendix A), those who have received repeated blood transfusions, those with a history of dialysis, and those with lifestyle risks of infection, etc.)	Please check one: □ Student is NOT AT RISK of past infection (The student's country of origin is NOT a Hepatitis B endemic country & they do NOT have a history risk factors). OR □ Student is AT HIGH RISK of past infection

Last edited: 22 March 2024 **3** | P a g e

	 A student with a POSITIVE Anti-HBc (core) and/or HBsAg requires a physician letter explaining the results. If a student has low Anti-HBs of less than 10u/L, the student will need to receive boosters (at the appropriate intervals) as per the attached AHS Hepatitis B Algorithms (Appendix B &C) until a positive Anti-HBs of 10u/L or greater, is achieved. If a student has received a total of 2 complete series of the hepatitis B vaccine and their Anti-HBs remain low (<10 u/L), the student is considered a non-responder, and no further hepatitis B vaccination is recommended. The student will then need to have an HBsAg completed (regardless of risk) and will require a letter stating they are a non-responder from a physician. 	Mandatory Serology: Required for all students Anti-HBs: Date: Result:U/L Interpretation: POSITIVE NEGATIVE • COPY OF LAB RESULT MUST BE ATTACHED TO THIS FORM If required (High- Risk Students only): Anti-HBc (core): Required for those students at high risk of past Hepatitis B infection Date: Result: POSITIVE NEGATIVE NOT APPLICABLE • COPY OF LAB RESULT MUST BE ATTACHED TO THIS FORM HBsAg: Required for those students at high-risk of past Hepatitis B infection or those considered non-responders to Hepatitis B immunization Date: Result: POSITIVE NEGATIVE NOT APPLICABLE • COPY OF LAB RESULT MUST BE ATTACHED TO THIS FORM Letter from physician explaining results: Required for students who have a positive Anti-HBc, a positive HBsAg or a student who is considered a non-responder to Hepatitis B immunization Letter attached
SEASONAL INFLUENZA	Recommended for ALL Health Care Students.	1 dose annually.
Health Care Provide	r Name Health Care Provider Signature Da	Clinic Stamp:

Student Name:

Last edited: 22 March 2024

TB M	<u> 1antoux Skin Tes</u>	st Intake Form		
First Name: Cell Phone Number:	Last Name: DOB:	AHC #:	Date:	
Address:		Ci	ity	Prov:
Emergency Contact Name & Phone Nu	ımber:			
Do you take any medications:Allergies:		Ema	 nil:	
<u>-</u>				
Check all that apply:				
Coughing for three or more weeks				
Coughing up blood or mucus				
Chest pain, or pain with breathing or co	oughing			
Unintentional weight loss				
Fatigue				
Fever, Night sweats or Chills				
Loss of appetite				
Live or are from a country where TB is	common (Latin A	America, Africa and	Asia)	
In contract with people who have TB o	r treat people with	high risk.		
Have had the BCG (Bacille Calmette-C	Guerin vaccine) va	ccine, sarcoidosis, o	or Hodgkin's lyı	mphoma
Have HIV/AIDs or a positive test resul	t before			
Have had one or more of the following Chickenpox vaccine	vaccines in the pa	ast 4 weeks: four we	eeks AFTER a (Covid, MMR or
None of the above				
I consent to having a Mantoux Tuberculin S reactions can be monitored, & agree to havi and other healthcare providers. *				
Yes, I consent	Signature:			
No I understand that I am responsible for booki do not then the test must be repeated. *	ng a follow up apı	pointment within 48	3 – 72 hours foll	owing my test. If I
Yes, I agree	Signature:			=
No				
	OFFICE USE	ONLY		
Test Date:	R	eading Date:		
Time:	R	EADING Time:		
TUBERSOL (DIN:00317268) – Sanofi Past LOT:	eur Ro	eading:	mm	
EXPIRY:	In	nitial:		

Initial: Site: Right/Left Forearm



GENERAL LABORATORY REQUISITION

Scanning Label or Accession # (lab only)

Dynal IFF Medical Labs: 1 (800) 661-9876 or (780) 451-3702

				D	Alberta Precision Laboratorio			12					
	PHN / Healthcare		xpiry:	Alte	rnate Identifier				7 l				
nt	Legal Last Name		хриу	Leg	al First Name		Middle Nam	ne		Da	ate of Bir	rth <i>(dd-Mon-yyyy)</i>	
Patient	Preferred Name			☐ Male ☐ Female ☐ X (Non-Binary/Prefer not to Disclose)				;)		Phone			
	Address			City	/ Town			Prov	ince	Po	ostal Cod	de	
	Authorizing Providence	der Name (Last, Firs	t, Middle)		Authorizing Provider Name (Las	st, First, Mic	idle)		Authorizi	ng Prov	/ider Nar	me (Last, First, Midd	dle)
er(s)	Address			To 1	Address			To 2					
Provider(s)	CC Provider ID	CC Submitter ID	Legacy ID	Copy -	Phone			Copy	Phone				
_	Clinic / Building N	lame		Ĭ	Clinic / Building Name				Clinic / B	uilding l	Name		
	Collection	Date (dd-Mon-yy)	yy)	Tim	ne (24h)	Location				Co	ollector II	ID	
	Routine Stat	Requisition Date			Denotes a fasting test Special instructions, see web	site		Hou	rs Fasting	1		☐ Third Party Bill? Client)
	ematology / Coag				docrinology			Clin	ical Infor	mation	1		
	CBC and Different	tial □ CBC n	o Differential		tisol:	□ DM (4.50	0.4000)						
	D-dimer Fibrinogen				tandom □ AM (0700-1000) □ stradiol	□ PM (150	10-1800)						
	NR				ollicle Stimulating Hormone (FS	SH)		Dru	g Levels	/ Monit	toring		
	Reticulocyte Coun	it			uteinizing Hormone (LH)				hanol Lev				
	neral Chemistry				arathyroid Hormone (PTH)				apeutic D				
	Albumin Alkalina Phasphat	acc (ALP)		☐ Progesterone				Route		Oral [□ IV □ Other		
	Alkaline Phosphat Alanine Aminotrar			☐ Prolactin ☐ Testosterone, Total			Dose RegimenHow Long on Current Regimen?						
Bili	rubin:		and Conjugated	☐ Thyroid Stimulating Hormone (TSH)			Date of Last Dose or IV Complete						
	Calcium	(000)			hyroid Stimulating Hormone (T	SH), Progr	essive	Time of Last Dose or IV Complete Date of Next Dose or IV Start					
	C-Reactive Proteil Creatine Kinase (,			munology / Serology pstein - Barr Virus Serology - Ig	aN4		-	of Next L of Next E				
	Creatinine (eGFR				lepatitis A Virus Acute Serology				arbamaze			⊓ ⊐ Phenytoin, Total	
	,	Sodium ☐ Potass	ium	☐ Hepatitis A Virus Immunity Serology - IgG				☐ Cyclosporine Pre Dose ☐ Sirolimus					
	Ferritin	Transferase (GGT)		☐ Hepatitis B Surface Antigen ☐ Hepatitis B Surface Antibody				☐ Cyclosporine 2h Post ☐ Tacrolimus ☐ Digoxin ☐ Theophylline					
	Glucose Fasting)	☐ Hepatitis C Virus Serology				☐ Lithium ☐ Valproate					
	Glucose Random			☐ HIV 1 and 2 Serology (Antigen and Antibody)				☐ Phenobarbital ☐ Other					
	Hemoglobin A1c HCG, Serum (Qua	antitativo)		☐ Mononucleosis Screen ☐ Rheumatoid Factor				Antibiotics: Gentamicin □ Pre □ Post □ Interval □ Othe					I □ Othor
		l A (IgA) □ G (IgG	G) □ M (IgM)	☐ Rubella Immunity Serology - IgG					amycin			□ Post □ Interva	
	_ipase	(3)	, (0)	□ Syphilis			Vancomycin ☐ Pre ☐ Other						
	Magnesium			_	rdiology			_	e Drug T			3	
	Phosphate Prostate Specific	Antigen (PSA)			Electrocardiogram G to be read by:			Reason for Request □ Opioid Dependency Panel					
	Protein Electropho	0 ()		□ DynaLIFE Panel □Other			What is the Treatment Regimen?						
	Total Protein			Transfusion Medicine				uprenorph	ine		☐ Methadone		
	Jrate	Sheleeterel	Fui altro ani al co	☐ Direct Antiglobulin Test (DAT)			☐ Morphine ☐ Hydromorphone						
	∟ipid Panel □ C Cardiovascular Di	sease Risk Assess	Triglycerides ment	☐ RHIG Eligibility, Prenatal Type & Screen - separate process required, contact lab				□ Otherab OR					
	(includes Lipid Pa			Prenatal Type & Screen - use CBS Perinatal Requisition			tion ☐ General Toxicology Panel						
Required History:				Sterile Body Fluid			_				Trichomonas	1.0	
Systolic Blood Pressure (mmHg) Tobacco Use			Yes □ No	☐ Fluid Type Source Test(s)				Vagina ¹	& Gono	imea 5	Screen	ii Screen	
	Treated for High blood pressure ☐ Yes ☐ No Urine			· /				Endocen	vical ²		¹ Aptima Multitest sv label, PINK shaft)	vab (Orange	
	Diabetic		Yes □ No		Jrinalysis				Urine, Fi			² Aptima Unisex swa	b (White label,
	Chronic Kidney Di Atherosclerosis		Yes □ No Yes □ No		umin (Creatinine Ratio)	□ Randor	n □ 24h		Urethra ² Throat ¹		Rectal ¹ Eve ¹	³ Aptima Urine Colle (Yellow label)	ction kit
	First Degree Rela		. 30 🗀 110		atinine	□ Randor			ichomona				
	(M<55Y / F<65Y)		Yes □ No	4	tisol	□ D= 1	□ 24h		emale > 1		Ewale.	umidaal?	Supt 0 = 1 1 2
	Icose Tolerance	nal Diabetes Scree	en (GDS)	1	tein Electrophoresis al Protein (Creatinine Ratio)		n □ 24h n □ 24h		Vagina ¹		⊏⊓docei	ervical ² Urine, F	rist Catch ³
		e, Gestational, 2h			Creatinine Clearance 24h Ht			Auc	onar 10				
	Glucose Toleranc				Urine */		3	1					
	scellaneous	0- '- '-	- 50 74) **		al Volume			1					
	-11 Colorectal Ca H. pylori * <i>I</i>	ncer Screening (Ag	je 5U-74) 1	Sta	rt Date Start	t Time							
	Temoglobinopath	y Investigation		End Date End Time									



Immunization Record

Central Point Pharmacy, 10382-105 Street NW, Edmonton AB T5J 1E6

Phone: (780) 250-2616 Fax: (780) 250-2617

PATIENT INFORMATION

First Name	Last Name	Gender	DOB	Weight		
Address		Health Car	d #	Phone Number		
Emergency Contact	ency Contact Relationship to Patient		Phone Number	Contact's Other Phone Number		

SCREENING QUESTIONNAIRE

SCREENING QUESTIONNAIRE				
Are you experiencing any cold, flu or COVID-19-like symptoms, even mild ones?		Yes	No	Unsure
Have you travelled to any countries outside Canada (including the United States) within the last 14 days?	Yes	No	Unsure	
Did you provide care or have close contact with a person with confirmed COVID-19?		Yes	No	Unsure
Are you allergic to any medications including vaccines?		Yes	No	Unsure
Do you have an allergy to kanamycin, neomycin, gentamicin, thimerosal, chicken protein, polymixin or gelatin?		Yes	No	Unsure
Have you ever had a severe, life threatening reaction to a past vaccination?		Yes	No	Unsure
Have you had wheezing, chest tightness or difficulty breathing within 24 hours of getting a vaccine?		Yes	No	Unsure
Are you allergic to latex gloves?	Yes	No	Unsure	
Have you had Guillain-Barre Syndrome within 6 weeks of getting a vaccine?		Yes	No	Unsure
Do you have a new or changing neurological disorder?		Yes	No	Unsure
Do you take a blood thinner or have a bleeding disorder?		Yes	No	Unsure
Pharmacist-Will you be administering a Live Vaccine? (If "No", skip the following questions)		Yes	No	
Do you have a medical condition that can weaken your immune system? (eg. Leukemia, Lymphoma, HIV/AIDs)		Yes	No	Unsure
Are you taking any medications that can weaken your immune system within the past 3 months? (eg Prednisone etc)				Unsure
Have you received any other vaccines in the last 4 weeks?	Yes	No	Unsure	
Are you or do you think you might be pregnant?	N/A	Yes	No	Unsure

CONSENT GIVEN BY PATIENT/AGENT

sheets provided to me. I have had the chance minutes (or time recommended by the pharm reaction to any component of the vaccine. So experience such a reaction following vaccina and/or antihistamines to try to treat this react anaphylactic reaction may include hives, diffi	e to ask questions, and answers were given to macist) after getting the vaccine. I am aware that i ome serious reactions called "anaphylaxis" can be tion, I am aware that it may require the administration and that 9-1-1 will be called to provide additioulty breathing, swelling of the tongue, throat, and mergency treatments that I had received, or a coll confirm that I want my child to receive	cout the vaccine as outlined in the vaccine information by satisfaction. I agree to wait in the pharmacy for 15 to possible (yet rare) to have an extreme allergic elife-threatening and is a medical emergency. If I action of epinephrine, diphenhydramine, beta-agonists, anal assistance to the immunizer. The symptoms of an d/or lips. In the event of anaphylaxis, I will receive a by will be provided to my agent or EMS paramedics.
Patient/Agent & Relationship	Patient/Agent Signature	Date Signed
	e above named patient is capable of providing con	nsent for and e given to patient.
Pharmacist	Pharmacist Signature	Date Signed

Prescription Authorization

Patient:	
Address:	
DOB:	
Phone:	

Engerix-B 20mcg/mL Generic Name: Hepatitis B Surface Antigen (Recombinant) Disp Qty 1 DIN 02487039 INJECT 1ML INTRAMUSCULARLY (0,1,6 MONTHS)	Approved Qty 1 Repeats 2
MMR II Vaccine 0.5ml Generic Name: Measles/Mumps/Rubella Virus Vaccine Disp Qty 1 DIN 00466085 INJECT 0.5 ML(S) SUBCUTANEOUSLY (0,28 DAYS)	Approved Qty 1 Repeats 1
Varivax III 1350 Unit/0.5mL Generic Name: Varicella-Zoster Virus Vaccine Disp Qty 1 DIN 02246081 INJECT 0.5ML SUBCUTANEOUSLY (0, 3 MONTHS)	Approved Qty 1 Repeats 1
Boostrix Publicly Funded Generic Name: Publicly Funded Tdap Vaccine DIN 02247600 INJECT 0.5 MLS INTRA MUSCULAR	Approved Qty 1 Repeats

Prescriber Name (print name)	Raj Manhas	ID#	14127
Prescriber Signature		Date	